The Essence of Basic Research Innovation At CLYTE
The Story Behind the Name CLYTE
The name CLYTE is a fusion of Clytie and Cyte, embodying both mythology and science. # CLYTE Definition & Meaning
​
Clytie—also known as Clytia—was a water nymph in Greek mythology, deeply connected to the sun and its cycles. Transformed into a sunflower, she came to symbolize growth, renewal, and the relentless pursuit of knowledge. Cyte, derived from cellular biology, refers to cells—the fundamental units of life and the focus of scientific exploration.
​
Phonetically, CLYTE echoes the word light, a timeless symbol of illumination, discovery, and insight—values at the heart of research and innovation.
​
This carefully crafted name reflects the company’s commitment to life sciences and biomedical research, rooted in a passion for progress, discovery, and the advancement of knowledge.
CLYTE's Mission of Research Standardization
Basic research is the foundation for progress across all fields. In biomedical and life sciences, it drives groundbreaking discoveries that tackle some of the most significant challenges to human health.
Nevertheless, many preclinical research procedures are extremely time consuming, redundant, and may result in non-reproducible data!
​
CLYTE is an AI Biotechnology startup, aiming to reform those procedures to make them efficient, timely, and standardized, using AI in healthcare and cutting-edge technologies.
CLYTE's Journey of Innovation
Early 2024 we started official development of our first product CytCut 1.0 (formerly known as CellCut). A simple tool for applying uniform and unique scratches for 2D scratch assays. Currently under "First-client initiative" the tool has received overwhelmingly positive feedback, by allowing standardized and uniform scratches which eliminates human user application variability in the assessment of the assay.
​
In Sprint of 2025 our flagship AI model SOφ (Sophie) was developed; published in August of 2025 for researchers and students to use cutting-edge AI for assay design, analysis, and troubleshooting.
​
On May 2024 our biggest and most ambitious project was started. Cadmus a tool for cell culture monitoring, began development on May and version 0.5 of the device was tested internally. Following 50+ customer discoveries and user feedback, the new version of the device is currently under development with prospect of release for "First-client initiative" for Winter 2026, and mass market release in Q4.
Next Steps For CLYTE
Over 2025 we aim to expand our "First-client initiative" and release online services and tools for research data analysis.
​
CLYTE also hope to gain support of allies, industry leaders, and investors to finalize project Cadmus for market release in 2026; A project with immense impact on healthcare industry, utilizing AI in healthcare, and reforming how cell cultures are done not only in basic research side (drug development and testing, immunity research, etc.), but also in patient care, with reducing culture failures in procedures such as cell therapy and personalized cancer treatments.
The Team Behind CLYTE
-
Mojtaba Javid | Founder, Lead Engineer : Mojtaba has B.S. in Computer Science (2024), is the founder of CLYTE, leading product design and development. He has been designing implants and biomedical tool as a freelancer starting in high school. Throughout his undergrad he worked on multiple research projects and was involved in development of a student assessment and background matching algorithm for a UW-Health project. After graduation with more freelance work knocking on his door, he realized there is a market for high-throughput devices in biomedical research and founded CLYTE. His work as an Engineer at Cornell University’s Rev: Ithaca Startup Works incubator has honed his business and technical prowess in leading CLYTE.
-
Dr. Fahimeh Tabatabaei | Co-founder, Biomedical Expert : Holds a DDS and a Ph.D. in Tissue Engineering, bringing over two decades of experience in biomedical and life sciences research. Dr. Tabatabaei is a former university department head, industry biomedical expert, and an award-winning researcher; providing expertise and aligning our products' functionality with end-user needs.
-
Michael Yenik | Lead Electrical Engineer, Entrepreneur : Holds a B.S. in Computer Engineering. He is a former Software Engineer at Google and a Firmware Engineer at Intel, providing elite engineering discipline and expertise in developing robust and scalable technology. His company Acid Rain Technology is a global sensation in music synthesizer industry.
-
Vladimir Baranov | Business & strategy Lead : Hold multiple MBAs from renowned institutions across the world. With more than a decade of experience in leading and advising great businesses, Vlad provides crucial business and strategic mentorship to guide CLYTE’s commercialization strategy and growth. His mentorship has propelled many startups to great success over the years.
FAQs
- 01
CLYTE is an AI biotech startup focused on developing devices and AI in healthcare research, optimizing biomedical and life science research procedures through its innovations.
The Name CLYTE was created by fusion of Clytie (the sunflower nymph symbolizing seeking of light and knowledge) and Cyte (Biological Cell in Latin and commonly used in biomedical research terminology)
- 02
Usually our products will be available within a year that they are announced for FCI beta testing. Prior to commercial availability, you can receive our products for free through our FCI program.
- 03
Yes! While we offer variety of services and innovations, almost all of our products involve Artificial Intelligence (AI). Our mission is to develop tools for AI in healthcare research and bring AI-on-edge practices to transitional sciences.
Notably, Cadmus is a AI-on-edge device for cell culture monitoring. And our Latest product Sophie AI, is an expert assistance in biomedical research development.
- 04
We have completed a private investors / friend and family, pre-seed investment round so far. We are planning to do a more expanded seed investment round, during Q1 of 2026.
We had the goal of testing CytCut, patenting it, and launching it for pre-order; as well as launching Sophie AI. With these milestones met, and great global traction of our products, we are ready to confidently raise further funds toward 10xing our brand.
- 05
We plan to finish FCI beta testing for CytCut by the end of Q2 2025, with a product launch in Q3 2025. We will expand partnerships with FCI partners during the product launch, followed by Series A fundraising in Q4 2025 for market expansion and Cadmus project completion. Cadmus derivative product Beta FCI testing is scheduled for Q1 2026, with a product launch in Q3 2026. Series B fundraising and Main Cadmus Beta FCI testing will occur in Q4 2026. We have a similar product-launch pattern planned for three more products.